热门资讯> 正文
Aeterna Zentaris报告第四季度业绩
2024-03-27 20:18
- Aeterna Zentaris press release (NASDAQ:AEZS): Q4 total revenue for was $0.1 million as compared to $2.5 million for the same period in 2022, representing an decrease of $2.4 million, this decrease is primarily due to a $2.5 million decrease as a result of the termination of the Company’s agreement with Novo Nordisk Healthcare in May 2023, offset by a $0.1 milling increase in product sales.
- EPS loss of $1.16
More on Aeterna Zentaris
- Seeking Alpha’s Quant Rating on Aeterna Zentaris
- Historical earnings data for Aeterna Zentaris
- Financial information for Aeterna Zentaris
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
